Cerebrovascular disease is the third leading cause of death in the US. 13 Carotid artery atherosclerotic disease may account for up to 30% of all strokes. 16, 22 Results in several clinical trials have shown a benefit for CEA over conservative medical management in preventing strokes in patients with CA stenosis. In 1991, the NASCET demonstrated a 17% absolute risk reduction for ipsilateral stroke over 2 years with endarterectomy compared with medical management in symptomatic patients with severe CA stenosis of at least 70%. 17 More recently, CEA in patients with symptomatic but more moderate stenosis of 50 to 69% has been shown to reduce the absolute risk of ipsilateral stroke over 5 years by 6.5%. 3 Patients included in the NASCET were younger than 80 years of age and did not have organ failure or cancer that was judged likely to cause death within 5 years, nor did they have nonatherosclerotic CA disease or cardiac disease associated with thromboembolic symptoms. 17 Patients were also excluded if they had previously undergone an ipsilateral CEA. Carotid angioplasty and stent placement has been advocated in these high-risk surgical patients.
this procedure. In an effort to reduce the incidence of this complication, cerebral protection devices have been developed. 18 These devices include distal filters or balloons designed to filter or divert emboli, or that use flow reversal in the CA to prevent distal embolization. Based primarily on the results of the SAPPHIRE trial, which was performed without an unprotected angioplasty control group, several physicians have recommended that carotid angioplasty and stent placement procedures only be performed with protection devices.
All of these protection devices add complexity and additional instrumentation to the angioplasty and stent placement procedure. Whether the risks inherent in the use of these devices outweigh their benefits has not been established. Our goal in this study was to report our experience with carotid angioplasty and stent placement without the use of cerebral protection devices. Because the current standard of care at our institution is endarterectomy for patients with surgically amenable CA stenosis, all the patients in this series were considered poor surgical candidates by referring surgeons. This is a retrospective study of patient characteristics, techniques used, and the resulting procedural and 30-day complication rates. Factors associated with the occurrence of intraprocedural thromboembolic events were investigated.
CLINICAL MATERIAL AND METHODS

Patient Data
Between March 1, 1996 , and December 31, 2003, 167 carotid angioplasty and/or stent placement procedures were performed without cerebral protection devices in 152 patients at our institution. Seven of these patients underwent angioplasty alone. Institutional review board approval was obtained for the study and written informed consent was obtained for the procedures. The patients' medical records were reviewed and the following characteristics were recorded: age, sex, symptoms, previous endarterectomy, failed endarterectomy, history of dissection or radiation therapy, other occlusions, hypertension, diabetes, peripheral vascular disease, coronary artery disease, MI, or ischemic stroke. The specific reasons for referral were recorded (based on NASCET exclusion criteria), and included surgically inaccessible lesions, elderly patients (age Ͼ 79 years), medical problems causing high surgical risk, cancer likely to cause death within 5 years, previous ipsilateral CEA, or nonatherosclerotic CA disease (for example, dissections or pseudoaneurysms). Recorded information regarding treatment included the vessel treated, date of the procedure, percent stenosis before and after the procedure, stent and other devices used, location of the lesion, timing of angioplasty, anesthesia used, and the type of femoral artery closure. The intraprocedural and 30-day complication rates were also determined.
Surgical Procedure
All patients initially underwent diagnostic cerebral angiography on a dedicated biplane neuroangiographic unit (Neurostar; Siemens AG, Munich, Germany). Intravenous conscious sedation was used in 147 procedures. The remaining 20 procedures were performed after induction of general anesthesia. Arterial access was transfemoral for all procedures. Stenosis was documented in either the ICA, ECA (one case), or CCA (Fig. 1) .
In the 52 procedures completed prior to 2000, patients were premedicated with 325 mg aspirin administered orally each day for 5 days before the procedure. All subsequent procedures were performed after premedication with 75 mg clopidogrel bisulfate (Plavix; Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, New York, NY) administered orally each day in addition to aspirin. Using intravenous heparin, the activated clotting time was maintained between 250 and 300 seconds during the procedures.
For the interventional portion of the procedure, a No. 6, 7, or 8 French long sheath (Shuttle; Cook, Inc., Bloomington, IN) or the equivalent was placed in the CA proximal to the stenosis. Intracranial images were routinely obtained before and after the interventions to confirm patency of intracranial vessels. The stenosis was then crossed with a 0.018-in exchange guidewire (Roadrunner; Cook, Inc.) over which the angioplasty balloon and stent were advanced. Intravenous atropine or glycopyrrolate (American Regent Laboratories, Inc., Shirley, NY) was administered in 51 of the 167 procedures for prophylaxis or treatment of bradycardia.
In all, 169 self-expanding stents were used: 89 Smart stents (Cordis Corp., Miami Lakes, FL); 46 Wallstents (Boston Scientific Corp., Natick, MA); 32 Precise stents (Cordis Corp.); and two Symphony stents (Boston Scientific Corp.). Three balloon-expandable devices were used: two Palmaz stents (Cordis Corp.) at the CCA origins and one NIR stent (Boston Scientific Corp.) in a proximal CCA.
Two stents were placed in 10 patients, and three were delivered in one individual. Procedures in which multiple stents were used were performed for the following reasons: inadequate coverage of a long stenosis (six procedures); two separate areas of stenosis (three placements); an intimal flap noted at the margin of the first stent (one operation); or to stabilize potential nonvisualized coil components in the endovascular occlusion of an ophthalmic artery aneurysm (one procedure). Aside from three procedures in which 50% residual stenosis was found and one with 40%, all others resulted in less than 30% residual stenosis.
Of the 160 stent placement procedures, balloon angioplasty was required in 126 cases before delivery of the device and in 87 cases after stent insertion. Seventytwo cases required both pre-and postinsertion angioplasty. The stent size conformed to the largest diameter of the artery to be treated. In 86 procedures a stent was placed across the CA bifurcation; however, the ECA remained patent in all cases. No cerebral protection devices were used.
Femoral artery hemostasis was obtained using a closure device in 65 procedures. The devices used included 49 Perclose (Abbott Laboratories, Abbott Park, IL), 15 AngioSeal (St. Jude Medical, Inc., St. Paul, MN), and one Duett (Vascular Solutions, Inc., Minneapolis, MN).
Patients were monitored in an intensive care unit after the procedures and discharged the following day, with the exception of those who suffered periprocedural neurological symptoms. Aspirin and Plavix therapy were contin-ued for 30 days postprocedure and an aspirin regimen was continued for life.
Data Analysis
Patients were grouped in the following categories based on the underlying indication for the procedure: 1) symptomatic atherosclerotic stenosis; 2) asymptomatic atherosclerotic stenosis (including restenosis after endarterectomy or angioplasty and stent insertion); 3) dissection with or without pseudoaneurysm; and 4) stretched coils after placement for aneurysm occlusion. Patients were classified as symptomatic if they had experienced a TIA, stroke, or ischemic ocular event in an arterial territory distal to the target lesion. Patients with restenosis after angioplasty and stent insertion were considered symptomatic only if they experienced ischemic symptoms after their last procedure. Patients with restenosis after CEA were grouped into the first or second categories, based on whether ischemic symptoms had occurred or recurred after their surgery.
Baseline risk factors associated with the occurrence of intraprocedural thromboembolic events (stroke, TIA, or distal thromboembolism requiring fibrinolysis that did not result in a clinical deficit) were investigated using chisquare or Fisher exact tests (p Ͻ 0.05 accepted for statistical significance).
RESULTS
Of the 152 patients, 57 were women and 95 were men, and their mean age was 64 years (range 19-92 years). The baseline medical conditions of patients in this series are listed in Table 1 , and the reasons for patient referrals are given in Table 2 . Seventy-six of the 152 patients presented with focal neurological symptoms including hemispheric or ocular TIAs or strokes, in a vessel territory distal to an atherosclerotic CA stenosis. Seven of these 76 patients
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Carotid angioplasty and stent delivery without protection presented with symptomatic stenosis measuring less than 70%; the least stenotic lesions (two cases) measured 50%. These were treated because of ulcerated plaque and high-pressure gradient. Seventy-eight procedures were performed in these 76 symptomatic patients.
Fifty-eight patients had asymptomatic atherosclerotic CA stenosis. This group included five in whom asymptomatic restenosis had occurred after angioplasty for initially symptomatic stenosis. Sixty-two procedures were performed in these 58 patients. Of these, 25 procedures were performed in 21 patients in whom dissection and/or pseudoaneurysm were diagnosed. Thirteen of these 21 patients presented with symptoms of ischemia or cranial neuropathy. Finally, two other patients were treated with stents to secure the stretched end of an endovascular coil used for intracranial aneurysm treatment.
The procedure-related permanent symptomatic ischemic complication rate was four (2.4%) of 167. This included three hemispheric strokes and one retinal embolus. All events occurred in patients with symptomatic atherosclerotic stenosis (78 procedures, 5.1%). None of the procedures performed in patients with asymptomatic stenosis (62 procedures), dissection/pseudoaneurysm (25), or stretched coils (two) resulted in a permanent deficit.
The procedural TIA rate was six (3.6%) of 167. Intraprocedural TIAs occurred in three of the 78 operations performed in patients with symptomatic atherosclerotic stenosis. In one case this was due to distal thromboembolism that was successfully lysed with no residual deficit. None of the patients with asymptomatic stenosis suffered a TIA. The last three TIAs occurred in the 23 patients with diagnoses of dissection/pseudoaneurysm or stretched endovascular coil.
An asymptomatic thromboembolic event occurred in one symptomatic patient; this thrombus was successfully lysed. In the 129 patients with atherosclerotic CA stenosis, in whom use of a protective device might be considered, eight clinically or angiographically identified thromboembolic events occurred. All eight events occurred in the 76 symptomatic patients (p = 0.01; Table 3 ). Clinical characteristics in the eight procedures involving patients with procedure-related thromboembolic events are compared in Table 4 with those with no immediate neurological complications.
The rate of procedure-related, asymptomatic, angiographically confirmed abnormalities was seven (4.2%) of 167. These included the embolus to a middle cerebral artery branch mentioned earlier, which was successfully treated with Retavase (Centocor, Inc., Malvern, PA); an in-stent thrombus for which treatment with ReoPro (Centocor, Inc.) failed; a possible small thrombus seen at the distal margin of a stent 1 week postprocedure; decreased flow through an already stenotic ECA; a stent that was displaced from its delivery balloon and successfully snared; a raised intimal flap, which resulted in discontinuation of the procedure with no intervention being performed; and one incompletely dilated stent at the level of the CA bulb. The patients remained free of neurological symptoms despite all of these angiographic findings.
There were a total of three nonneurological vascular complications. These included a retroperitoneal hematoma with pseudoaneurysm formation, an episode of decreased distal pulses that required angioplasty of the common femoral artery, and one emergency embolectomy for absent distal pulses that eventually required a femoralpopliteal artery bypass. There were no significant hematomas in the groin that required blood transfusion or prolonged hospitalization. There were three other procedure-related complications, including transiently labile blood pressure in one patient, a case of supraventricular tachycardia successfully treated with labetalol (Bedford Laboratories, Bedford, OH), and an episode of transient chest pain with no electrocardiographically confirmed Y. Kadkhodayan, et al. abnormality. The total nonneurological complication rate was six (3.6%) of 167. The 30-day postprocedural follow-up results were available for 160 of the 167 procedures. These included three new cases of ipsilateral TIA, one new case of ipsilateral stroke with occlusion of the treated vessel, one case of posterior cerebral artery hemorrhage while the patient received warfarin therapy, and one central retinal artery occlusion at postoperative Day 2.
Four patients (2.6%) experienced other systemic complications at the 30-day follow-up review. One patient with asymptomatic stenosis died of an MI. Acute renal failure developed in another asymptomatic patient and this individual suffered an MI without ST segment elevation. The patient with the retroperitoneal hematoma mentioned previously underwent an evacuation procedure with a postoperative course complicated by adult respiratory distress syndrome requiring ventilation and tracheostomy, fever of unknown origin, and acute renal failure. In the fourth patient, who had a symptomatic atherosclerotic stenosis, a femoral infection developed, leading to surgical arterial repair.
One other treated vessel was known to have occluded at this time; however, the patient remained asymptomatic (asymptomatic angiographic abnormality rate of 0.6%). One patient underwent a contralateral endarterectomy and suffered a complicating stroke.
The composite (including intraprocedural stroke) 30-day stroke (seven patients) and death (one patient) rate was eight (5%) of 160.
DISCUSSION
Over the last decade, in multiple studies investigators have demonstrated the increased use of carotid angioplasty and stent placement procedures for patients with varying surgical risk. Given the compelling results of the NASCET, choosing to treat CA stenosis with angioplasty and stent insertion has generally required the patient to be ineligible for the NASCET protocol. An individualized analysis of the risks and benefits of medical, surgical, and endovascular treatments must be made. An important component of this analysis is the periprocedural complication rate.
In this series of 152 NASCET-ineligible patients, 167 carotid angioplasty and/or stent placement procedures were performed without cerebral protection devices, resulting in a low procedure-related permanent symptomatic ischemic complication rate of 2.4% and a procedurerelated transient symptomatic ischemic complication rate of 3.6%. The rate of asymptomatic angiographic abnormalities was 4.2%. The rate of nonneurological (that is, cardiovascular) complications was 3.6%. At 30 days postprocedure, the composite stroke and death rate was 5%; the rate of asymptomatic angiographic abnormalities was 0.6%; the rate of nonneurological complications was 2.5%.
The 30-day rates of perioperative stroke and death for patients with symptomatic stenosis in this series (six [7. 7%] of 78) were similar to those reported in the major CEA trials for symptomatic patients: NASCET (5.8%) and European Carotid Surgery Trial (7.5%). 6 No strokes but one death occurred during and after the 30 days in which 62 procedures were performed in 58 patients with asymptomatic stenosis in this series; this is comparable to the risk of stroke or death in the Asymptomatic Carotid Atherosclerosis Study (2.3%). 9 These trials had strict inclusion criteria that ensured acceptable surgical risk. The fact that the complication rates in our series, which was composed of a high-risk surgical population, approach those of the major endarterectomy trials is encouraging.
No cerebral protection devices were used in two of the three major angioplasty and stent placement trials mentioned earlier. The CAVATAS was a study of 504 patients randomized to receive endovascular or surgical therapy, which resulted in complication rates of 6.4 and 5.9%, respectively. 5 This study was limited because only 26% of the endovascular treatment group underwent stent placement. The Wallstent trial enrolled only 219 of 700 planned patients before it was halted. 2 The angioplasty and stent insertion group had a 12% complication rate at 1 year compared with 3.6% in the surgery group.
Our experience with carotid angioplasty and stent placement performed before the use of cerebral protection devices has been a positive one. Admittedly, the reported patient population is quite heterogeneous. More than half of the patients (89 [59%] of 152) were symptomatic. Many of the patients were referred for various medical comorbidities, including hypertension, diabetes, peripheral vascular disease, coronary artery disease, or a previous MI or cerebrovascular event.
The CA disease ranged from atherosclerosis and radiation therapy-associated stenosis to traumatic or iatrogenic dissection, pseudoaneurysm, and stretched endovascular coils from intracranial aneurysm treatment. Not all patients were treated for high-grade (Ͼ 70%) stenosis; other factors such as plaque surface morphology were taken into account.
A recent study has shown that plaque surface morphology on CA angiography is a highly sensitive marker of plaque instability.
14 AbuRahma, et al., 1 conducted an ultrasonography study of plaque morphology and investigated the clinical implications. They found that 84% of patients
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Carotid angioplasty and stent delivery without protection 5 with irregular plaques and 80% of those with heterogeneous plaques presented with TIA or stroke symptoms, compared with 19% of patients with smooth plaques and 29% of those with homogeneous plaques. Our data indicate that symptomatic patients are at higher risk for procedure-related thromboembolic events. The global CA stent treatment registry was used in a comparison between symptomatic patients treated with and without cerebral protection. Cerebrovascular events occurred in 5.9% of patients who did not receive protective devices and in 2.8% of those who received the devices. 20 In another review of CA stent placement procedures, researchers reported rates of 5.5 and 1.8%, respectively. 12 Based on these data, we believe that it may be appropriate to select symptomatic patients to undergo angioplasty and stent placement with cerebral protection devices.
Most recently, investigators in the SAPPHIRE trial looked for the end point of death, stroke, and MI at 1 year postprocedure in a group of 334 patients (67% male, mean age 72 years) with coexisting medical conditions that would increase the risks associated with surgery. 21 The patients were randomized to undergo CA stent placement (with the use of an embolus protection device) or CEA. The end point occurred in 12.2% of the group treated with stents compared with 20.1% of the group that underwent endarterectomy. The authors concluded that in this group of patients, CA stent placement with a cerebral protection device was not inferior to endarterectomy.
The SAPPHIRE cohort is similar to patients included in our series in terms of age, sex, and medical comorbidities. In the stent treatment arm, 85.5% of patients had hypertension, 25.3% had diabetes, 29.7% had a previous MI, 31.1% had a history of TIA, and 27.1% had a history of stroke. These numbers compare well with the baseline characteristics of patients in our series (Table 1 ). In addition, patients enrolled in the SAPPHIRE study were required to have a high risk of complications from surgery. The criteria for high risk included the presence of at least one of the following: clinically significant cardiac disease, severe pulmonary disease, contralateral CA occlusion, contralateral laryngeal nerve palsy, previous radical neck surgery or radiation therapy to the neck, recurrent stenosis after endarterectomy, or age older than 80 years. With the exception of patients with nonatherosclerotic disease (for example, dissection/pseudoaneurysm or stretched endovascular coil in 23 individuals), all of the patients included in our series were considered high risk by these criteria.
In the periprocedural period (Յ 30 days postoperatively), the cumulative incidence of stroke, MI, or death was 4.8% in those who were randomized to receive a stent in the SAPPHIRE study. In our study, four patients suffered a procedure-related stroke, three had permanent symptomatic ischemic complications at 30 days, and two had MIs (one death), making the rate of stroke, MI, or death in our series 5.6% (nine of 160). None of the asymptomatic patients suffered a stroke. The limitations of a retrospective study notwithstanding (complications may be underestimated), the similarity of the two periprocedural complication rates raises the question of the efficacy of protective devices in patients without symptomatic atherosclerotic disease.
Angioplasty and stent placement with the systematic use of cerebral protection devices is being compared with CEA in several ongoing multicenter randomized trials. 4 These include the Carotid Revascularization Endarterectomy versus Stent Trial and the EVA-3S study. The EVA-3S investigators recently recommended abandonment of unprotected angioplasty and stent placement because the 30-day stroke rate was 3.9 times higher (four of 15 compared with five of 58, not randomized) than in patients treated with cerebral protection. 7, 8 In both the Carotid Revascularization Endarterectomy versus Stent Trial and the EVA-3S study, cerebral protection is required in the angioplasty and stent placement arm. The protocols in two other ongoing trials do not require cerebral protection; however, these devices may be used at the discretion of the physician. 10, 19 The aforementioned trials include the International Carotid Stenting Study (CAVATAS-2) and the Stent Protected Angioplasty versus Carotid Endarterectomy trial.
Cerebral protection devices are not without complications. Crossing a high-grade stenosis with a filter or balloon-type protection device may not be possible or may result in complete occlusion of the vessel. Attempts to place these devices across the lesion may increase the risk of dissection or other damage to the vessel wall. In addition, the introduction of an additional device into a treated vessel adds to the complexity and cost of the procedure. On the other hand, these devices may provide neuropsychological benefit by preventing microemboli that are not clinically detected. Whether cerebral protection should be used routinely remains to be seen.
This series represents our comprehensive experience with carotid angioplasty and stent placement before the introduction of cerebral protection devices. The procedural and 30-day complication rates for this heterogeneous patient population have shown that unprotected carotid angioplasty and stent placement is safe and effective, particularly in patients without symptomatic atherosclerotic disease. The ongoing clinical trials will help establish the role of this procedure in stroke prevention.
